Cognision and SOMNOmedics Forge Strategic Partnership to Advance Sleep Biomarkers in Pharmaceutical Clinical Trials

LOUISVILLE, Ky., Sept. 24, 2025 /PRNewswire/ — Cognision, a leader in high-performance neurophysiological biomarker solutions and services, has announced a strategic partnership with SOMNOmedics AG, a global innovator in advanced sleep diagnostics technology. Through this collaboration, Cognision will provide SOMNOmedics’ next-generation polysomnography (PSG) solutions, purpose-built for the rigorous demands of pharmaceutical-sponsored clinical trials.

The partnership leverages Cognision’s expertise in providing complex neurophysiological assessments in regulated research environments with SOMNOmedics’ proven compact, mobile, and full-featured PSG technology. Together, the two companies will provide an end-to-end solution for sponsors needing precise and reliable sleep architecture data in therapeutic trials. This will empower sponsors to integrate robust sleep biomarkers into trials of drugs that treat abnormal sleep conditions or that may interfere with healthy sleep with the same confidence and performance that they expect from Cognision’s gold-standard electroencephalography (EEG) and event-related potential (ERP) biomarkers.

“Sleep endpoints are becoming increasingly important in CNS drug development, from neurodegeneration and neuropsychiatric disorders to pain and emerging psychedelic therapies,” said Dr. Igor Korolev, VP of Neuroscience and Digital Health for Cognision. “This partnership delivers best-in-class PSG solutions, streamlined deployment, centralized data management, and highly reproducible automated analysis – without the complexity, risk, and delays often seen in CNS biomarker trials.”

SOMNOmedics PSG systems are recognized worldwide for their unmatched signal quality, scalable configurations, and adaptability to both inpatient and home use – giving sponsors options for decentralized clinical trials (DCT). All PSG data will be managed within Cognision’s regulatory-compliant cloud-based Clinical Trial Data Management System (CTMS), providing near real-time sponsor access for faster decision making and adaptive trial designs.

“This is not just about providing equipment – it’s about ensuring every site, patient, and data point meets the industry’s highest standards,” said Denise Frahley, Director of US Sales. “Together our operational and technical innovations set a new benchmark for sleep measurement in pharmaceutical research.”

This partnership reinforces Cognision’s position as the go-to partner for neurophysiological endpoints in drug development with a proven expertise in protocol design, site enablement, data quality oversight, and full analytic capabilities, while expanding SOMNOmedics reach of its best-in-class sleep diagnostics technology in the pharmaceutical trial arena. Together, the companies are enabling the next wave of biomarker-driven, precision-targeted, CNS drug development.

About Cognision

Cognision provides advanced neurophysiological measurement services and solutions for clinical trials, specializing in EEG, ERP, and cognitive testing. The company delivers fully managed services – including protocol consultation, equipment logistics, site enablement and training, data monitoring and analytics, and data management – to ensure consistency, accuracy, and compliance across a broad range of pharmaceutical trials.

About SOMNOmedics AG

SOMNOmedics is a global provider of portable and stationary sleep diagnostics systems. Known for innovation, signal quality, and flexibility, SOMNOmedics supports clinicians and researchers in capturing high-quality sleep data for both patients care and clinical research.

For media inquiries or further information, please contact:

Nathan Alvarado
502-561-7005
Director of Business Development
nalvarado@cognision.com

View original content:https://www.prnewswire.com/news-releases/cognision-and-somnomedics-forge-strategic-partnership-to-advance-sleep-biomarkers-in-pharmaceutical-clinical-trials-302566011.html

SOURCE Cognision